DESTINY-Breast03 Phase 3 Study Results
Treatment Related TEAEs (Any Grade) Occurring in ≥10% of
Patients
Daiichi-Sankyo
1.6 mg/kg
(n=1)
3.2 mg/kg 4.8 mg/kg
(n=6)
6.4 mg/kg
(n=6)
(n=8)
8.0 mg/kg
(n=6)
9.6 mg/kg
(n=3)
Any treatment-related TEAE, n (%)
1 (100)
4 (66.7)
4 (66.7)
7 (87.5)
6 (100.0)
3 (100.0)
Total
(N=30)
25 (83.3)
Nausea
0
3 (50.0)
3 (50.0)
5 (62.5)
5 (83.3)
2 (66.7)
18 (60.0)
Fatigue
0
2 (33.3)
3 (50.0)
4 (50.0)
6 (100.0)
2 (66.7)
17 (56.7)
Vomiting
0
2 (33.3)
1 (16.7)
2 (25.0)
2 (33.3)
2 (66.7)
9 (30.0)
Neutrophil count decreased
0
0
0
1 (12.5)
3 (50.0)
3 (100.0)
7 (23.3)
Decreased appetite
1 (100)
0
0
4 (50.0)
1 (16.7)
0
6 (20.0)
Diarrhea
0
0
0
2 (25.0)
1 (16.7)
1 (33.3)
4 (13.3)
·
Treatment-related TEAES occurred in 25 patients (83.3%)
The most common treatment-related TEAEs of any grade were nausea, fatigue, and vomiting
One patient in the 9.6-mg/kg arm experienced grade 2 pneumonitis, which led to treatment discontinuation
Data cutoff: February 25, 2022.
TEAE, treatment-emergent adverse event.
ASCO 2022 #3002 Oral
102View entire presentation